Meeting
2015 ASCO Annual Meeting
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving anthracycline-cyclophosphamide (AC)-based chemotherapy.
Authors
Ian D. Schnadig
Compass Onc, Tualatin, OR
Ian D. Schnadig , Manuel R. Modiano , Allen Poma , Sujata Arora , Lee Steven Schwartzberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Symptom Management/Supportive Care
Clinical Trial Registration Number
NCT01500213; NCT01499849; NCT01500226
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9618)
DOI
10.1200/jco.2015.33.15_suppl.9618
Abstract #
9618
Poster Bd #
277
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).
First Author: Martin Chasen
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).
First Author: Bernardo Leon Rapoport
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non–anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC).
First Author: Daniel Powers
Poster
2015 ASCO Annual Meeting
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic therapy (MEC).
First Author: Paul Joseph Hesketh